: Potential explanations for the negative results in 12 trials on zinc lozenges 2 Statistical calculations for the Hemilä (2020) trial 5 Table S2 : Analysis Turner (2000) zinc gluconate trial with induced rhinovirus colds 9 Turner did not respond to this criticism, which indicates that the criticism has not been refuted.
+ low dose Ref 18 and 19
Zinc dose shown on the left-hand side is the planned dose, but the actual dose used by participants was not reported. 
80
This may be the only one of the 12 negative trials that does not have a clearly plausible explanation for the lack of benefit from the zinc lozenges, but there are possible explanations.
First, the calculation of dose 80 mg/day is based on the planned frequency of lozenge usage and not on reported/observed frequency of usage.
In the current trial by Hemilä (2020) the ratio of actual usage to planned usage was 5.1/6.0 = 85%. If the same ratio applied to Turner (2000) trial, the actual dose would have been 68 mg/day (= 0.85*80).
Mossad (1996) (2000)[9] included participants who had colds <36 hours and this longer delay between the start of symptoms and the start of treatment is also a potential reason for low efficacy in the Turner natural colds trial, assuming that rapid initiation of treatment might be optimal.
Finally, the same lozenge was effective (P = 0.035) in a parallel trial with induced rhinovirus type 39 colds. It is possible that the effect of zinc lozenges varies between viruses so that the discrepancy between the findings for natural colds and induced colds might be partly explained by the types of viruses causing the symptoms.
Statistical calculations for the Hemilä (2020) trial
All participants (n = 87) > CrossTable(HelZinki$Duration,HelZinki$Zinc, prop.r ="F", prop.c ="F", pr op.t ="F", prop.chisq ="F")
Total Observations in Table: 87 Table: 87
All participants (n = 87)
> RR <-coxph(zincsurv ~ HelZinki$Zinc, method = "efron") > RR Call: coxph(formula = zincsurv ~ HelZinki$Zinc, method = "efron") coef exp (coef) 
Participants WITH side effects (n = 31)
> ytas_oth <-subset(HelZinki, tas_othSE>0) > ytas_oth$tas_othSE [1] 6 3 6 3 6 3 6 2 4 2 3 2 1 4 6 6 5 4 4 1 3 1 4 3 1 6 1 2 5 3 3 > > > ytosurv <-Surv(ytas_oth$Duration, ytas_oth$Cured) > yRR <-coxph(ytosurv ~ ytas_oth$Zinc, method = "efron") > yRR Call: coxph(formula = ytosurv ~ ytas_oth$Zinc, method = "efron") coef exp (coef) 0.5 10 0.5 6 1.0 4 1.0 3 1.5 11 1.5 6 2.0 3 2.0 3 2.5 10 2.5 8 3.0 6 3.0 5 3.5 7 3.5 9 4.0 3 4.0 8 4.5 1 4.5 3 5.0 1 5.0 0 5.5 2 5.5 1 6.0 1 6.0 0 6.5 0 6.5 0 7.0 1 7.0 1 7.5 0 7.5 1 8.0 1 8.0 2 8.5 2 8.5 2 9.0 0 9.0 1 9.5 0 9.5 1 10 2 10 0 10.5 1 10.5 0 11 2 11 1 11.5 1 11.5 0 12 0 12.5 1 13 0 13.5 5 > survTurner <-Surv(Turner$days, Turner$cured) > RR <-coxph(survTurner ~ Turner$zinc, method = "efron") > summary(RR) Call: coxph(formula = survTurner ~ Turner$zinc, method = "efron") n= 136, number of events= 131 coef exp(coef) se(coef) z Pr(>|z|) Turner$zinc 0.3740 1.4536 0.1768 2.115 0.0344 * ---Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0. Nevertheless, Turner did not publish the effect of zinc lozenges on the RR scale and therefore the calculation is done above.
Turner reported:
"Between-group comparisons of the time to cold resolution were performed by means of the log-rank test, adjusted for study site" (p 1203, right-hand column) "The median duration of illness in zinc gluconate recipients was 2.5 days, in comparison with 3.5 days in the placebo recipients (P = .035)." (p 1204 left-hand column)
